• Home
  • Meet Dr. Jennifer Marquez
  • Drugs affected by PGx
  • Services offered
  • The Doctor Recommends
  • Frequently Asked
  • The Human Cost
  • For Patients
  • For Healthcare Providers
  • Contact Us
  • More
    • Home
    • Meet Dr. Jennifer Marquez
    • Drugs affected by PGx
    • Services offered
    • The Doctor Recommends
    • Frequently Asked
    • The Human Cost
    • For Patients
    • For Healthcare Providers
    • Contact Us

  • Home
  • Meet Dr. Jennifer Marquez
  • Drugs affected by PGx
  • Services offered
  • The Doctor Recommends
  • Frequently Asked
  • The Human Cost
  • For Patients
  • For Healthcare Providers
  • Contact Us

For Healthcare Providers

Pharmacogenomic (PGx) testing & comprehensive medication consulting services

Dr. Jennifer Marquez is ready to assist you in your medical practice. Her passion is helping both patients and their healthcare providers to optimize drug therapy. Please feel free to request a visit to your practice to learn about all the benefits that PharmDNA, LLC can offer you, your practice, and your patients. We are eager to meet with you if you want to learn more!

Request Clinic Visit

Literature Supporting PGx

There is a rapidly-growing body of robust literature supporting the implementation of PGx into clinical practice. The Clinical Pharmacogenetics Implementation Consortium (CPIC) produces guidelines that are peer-reviewed, regularly updated, and freely available (see link below) to guide drug therapy with certain gene-drug pairs in the presence of certain genetic variants. Many of these gene-drug pairs and genetic variants are well-studied, clinically significant and actionable in everyday medical practice.


Dr. Jennifer Marquez is trained to analyze and interpret the data in the 20-40 page genetic reports that result from PGx testing, as well as the related gene-drug pair guidelines and complexities of drug-gene, drug-drug, and drug-drug-gene interactions. Drug-drug-gene interactions can be very complex, and sometimes adding a second drug that interacts with a certain gene will cause something called phenoconversion to occur. This is a phenomenon that converts genotypic extensive metabolizers into phenotypic poor metabolizers of drugs. 


A few links and references are posted here for your convenience and review.


  • CPIC website (guidelines): www.cpicpgx.org
  • Dutch Pharmacogenetic Working Group (DPWG) website (guidelines): https://upgx.eu/guidelines/
  • PharmGKB website: https://www.pharmgkb.org/
  • FDA table of Pharmacogenomic Biomarkers in Drug Labeling: https://www.fda.gov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
  • Get The Medications Right Institute’s website: www.gtmr.org

2021 meta analysis showing PGx reduces hospitalizations (pdf)

Download

2021 article about integrating PGx into CMM models (pdf)

Download

2020 article highlighting the benefits of PGx implementation at University of Colorado (pdf)

Download

2020 PGx in cardiovascular disease article (pdf)

Download

2020 PGx in depression article (pdf)

Download

PGx improves health system performance (pdf)

Download

How Can I Help You?

I love connecting with other healthcare providers! Let me know how I can help you, or request a visit from me at your practice site.

PharmDNA, LLC

(706) 230-5230

Dr. Jennifer Marquez

Founder/CEO of PharmDNA, LLC

Copyright © 2022 PharmDNA, LLC - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept